Why Did Supernus Pharmaceuticals Plunge 28.73% Amid Fraud Concerns?

On April 8, 2025, Supernus Pharmaceuticals, Inc. experienced a significant drop of 28.73% in pre-market trading, sparking concerns among investors and analysts alike.

Investors in Supernus Pharmaceuticals, Inc. have been alerted to potential fraudulent activities, with legal firm Levi & Korsinsky encouraging affected parties to discuss their rights. This news has added to the uncertainty surrounding the company's stock performance.

Supernus Pharmaceuticals, Inc. has seen its target price lowered to $33.00, with an investment rating of HOLD. This adjustment reflects the current market sentiment and the company's recent performance.

The company's focus on developing and commercializing products for the treatment of central nervous system (CNS) diseases has been a key driver of its growth. However, recent developments have raised questions about its future prospects.